Lumosa Therapeutics Co., Ltd. 6535.TWO Stock
Lumosa Therapeutics Co., Ltd. Price Chart
Lumosa Therapeutics Co., Ltd. 6535.TWO Financial and Trading Overview
| Lumosa Therapeutics Co., Ltd. stock price | 194.5 TWD |
| Previous Close | 57.5 TWD |
| Open | 57.2 TWD |
| Bid | 55.1 TWD x 0 |
| Ask | 55.3 TWD x 0 |
| Day's Range | 53.9 - 57.2 TWD |
| 52 Week Range | 34.2 - 68.7 TWD |
| Volume | 1.69M TWD |
| Avg. Volume | 1.26M TWD |
| Market Cap | 8.99B TWD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.46 TWD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
6535.TWO Valuation Measures
| Enterprise Value | 9.38B TWD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 5.5138597 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Lumosa Therapeutics Co., Ltd. Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 62.88% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 68.7 TWD |
| 52 Week Low | 34.2 TWD |
| 50-Day Moving Average | 50.7 TWD |
| 200-Day Moving Average | 41.84 TWD |
6535.TWO Share Statistics
| Avg. Volume (3 month) | 1.26M TWD |
| Avg. Daily Volume (10-Days) | 1.58M TWD |
| Shares Outstanding | 163.1M |
| Float | N/A |
| Short Ratio | N/A |
| % Held by Insiders | 49.31% |
| % Held by Institutions | 2.26% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | N/A |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | 0.16 TWD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 14.56M TWD |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | N/A |
| Diluted EPS (ttm) | -0.95 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | N/A |
| Total Cash Per Share (mrq) | N/A |
| Total Debt (mrq) | N/A |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | N/A |
| Book Value Per Share (mrq) | 9.993 |
Cash Flow Statement
| Operating Cash Flow (ttm) | N/A |
| Levered Free Cash Flow (ttm) | N/A |
Profile of Lumosa Therapeutics Co., Ltd.
| Country | Taiwan |
| State | N/A |
| City | Taipei |
| Address | No. 3-2, Park Street |
| ZIP | 11503 |
| Phone | 886 2 2655 7918 |
| Website | https://www.lumosa.com.tw |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 47 |
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.
Q&A For Lumosa Therapeutics Co., Ltd. Stock
What is a current 6535.TWO stock price?
Lumosa Therapeutics Co., Ltd. 6535.TWO stock price today per share is 194.5 TWD.
How to purchase Lumosa Therapeutics Co., Ltd. stock?
You can buy 6535.TWO shares on the Taipei Exchange exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Lumosa Therapeutics Co., Ltd.?
The stock symbol or ticker of Lumosa Therapeutics Co., Ltd. is 6535.TWO.
Which industry does the Lumosa Therapeutics Co., Ltd. company belong to?
The Lumosa Therapeutics Co., Ltd. industry is Biotechnology.
How many shares does Lumosa Therapeutics Co., Ltd. have in circulation?
The max supply of Lumosa Therapeutics Co., Ltd. shares is 164.97M.
What is Lumosa Therapeutics Co., Ltd. Price to Earnings Ratio (PE Ratio)?
Lumosa Therapeutics Co., Ltd. PE Ratio is now.
What was Lumosa Therapeutics Co., Ltd. earnings per share over the trailing 12 months (TTM)?
Lumosa Therapeutics Co., Ltd. EPS is -1.46 TWD over the trailing 12 months.
Which sector does the Lumosa Therapeutics Co., Ltd. company belong to?
The Lumosa Therapeutics Co., Ltd. sector is Healthcare.